Insight Molecular Diagnostics will report Q2 results with a consensus EPS loss of $0.25 and revenue of $0.44M.
Insight Molecular Diagnostics Inc. (IMDX) will release its Q2 2026 earnings on August 10 after the market closes. Analysts expect a loss of $0.25 per share and revenue of $0.44M for the quarter.
The company has historically beaten EPS estimates over the past year. Prior consensus estimates and performance trends suggest continued challenges in profitability despite revenue expectations.
No immediate market reaction details were provided ahead of the release.